Latest Breaking News On - Can fite biopharma - Page 7 : comparemela.com

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

PETACH TIKVA, Israel, February 28, 2024 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation". This invention addresses the use of Namodenoson for the

Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the stock. Separately, HC Wainwright cut their target price on Can-Fite BioPharma from $34.00 to $18.00 and set a buy rating on the stock in a research report on Tuesday, […]

Equities Research Analysts' New Coverage for February 18th (AAU, ADES, AEZS, AIRG, AMS, AWX, BLPH, CALA, CANF, CBFV)

Equities Research Analysts' New Coverage for February 18th (AAU, ADES, AEZS, AIRG, AMS, AWX, BLPH, CALA, CANF, CBFV)

Can-Fite Shares Rise After Expansion of Licensing Deal

By Rob Curran Can-Fite BioPharma shares rose after the Israeli biotech concern expanded a licensing deal with Swiss firm drug-distribution firm Ewopharma to.